Therapeutic drug monitoring of Meropenem, Linezolide and Tigecyclin in liver failure. Quantification of liver function with Maximal Liver Function Capacity test (LiMAx-Test).
Recruiting
- Conditions
- K72.0Acute and subacute hepatic failure
- Registration Number
- DRKS00008888
- Lead Sponsor
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum. Klinik für Allgemein-, Visceral, und Transplantationschirurgie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 420
Inclusion Criteria
1. Existence of liver failure and indication of therapy with Meropenem, Linezolide or Tigecycline
2. Age >18<90
3. Existing inform consent (patient or legal caregiver)
Control Group:
1.Indication of therapy with Meropenem, Linezolide or Tigecycline and absence of liver failure
2. Age >18<90
3. Existing inform consent (patient or legal caregiver)
Exclusion Criteria
1. Allergy against Methacetin
2. Age <18>90
3. Pregnancy, breast feeding
3. Missing inform consent
4. patient cannot cooperate during study due to mental disturbance
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method